Hepatitis B Vaccine

Merck's Two-Dose Hepatitis B Vaccine Approved for Adolescent Use

Published in Medical Letter on the CDC and FDA, February 7th, 2000

Recent US Food and Drug Administration (FDA) approval of a 2-dose regimen of Recombivax HB, Merck & Co, Inc's vaccine to prevent hepatitis B, may help to protect adolescents 11 to 15 years of age against this disease.

This 2-dose regimen of 10 mcg/1.0 mL is an alternative to the 3-dose 5 mcg/0.5 mL regimen of Recombivax HB already used in children 0 to 19 years of age.

"Adolescents can be the hardest age group to fully vaccinate for hepatitis B," said Tom Vernon, MD, vice president, Public Health and Medical Affairs, Merck Vaccine Division. "Busy schedules leading to missed or postponed appointments, changes in physicians and healthcare plans and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2000-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry